Pancreatic adenocarcinoma: Molecular drivers and the role of targeted therapy

B Al-Share, N Hammad, M Diab - Cancer and Metastasis Reviews, 2021 - Springer
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …
被引用次数：9 相关文章

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy.

B Al-Share, N Hammad, M Diab - Cancer & Metastasis …, 2021 - search.ebscohost.com
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

B Al-Share, N Hammad, M Diab - Cancer metastasis …, 2021 - pubmed.ncbi.nlm.nih.gov
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

B Al-Share, H Nour, M Diab - Cancer and Metastasis Reviews, 2021 - search.proquest.com
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy.

B Al-Share, N Hammad, M Diab - Cancer Metastasis Reviews, 2021 - europepmc.org
Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the
many efforts channeled to improve its management. Although the mainstay treatment is still …